The CXCR4 Antagonist AMD3100 Has Dual Effects on Survival and Proliferation of Myeloma Cells In Vitro.
about
Targeting paraprotein biosynthesis for non-invasive characterization of myeloma biology.CXC chemokine ligand 12 protects pancreatic β-cells from necrosis through Akt kinase-mediated modulation of poly(ADP-ribose) polymerase-1 activity.Differential effects of CXCR4 antagonists on the survival and proliferation of myeloid leukemia cells in vitro.AMD3100 reduces CXCR4-mediated survival and metastasis of osteosarcoma by inhibiting JNK and Akt, but not p38 or Erk1/2, pathways in in vitro and mouse experiments.Initial assessment of the role of CXC chemokine receptor 4 after polytrauma.An antedrug of the CXCL12 neutraligand blocks experimental allergic asthma without systemic effect in micePCAF-mediated Akt1 acetylation enhances the proliferation of human glioblastoma cells.The CXCR4 antagonist plerixafor enhances the effect of rituximab in diffuse large B-cell lymphoma cell lines.Cell Trafficking in Multiple MyelomaSublytic C5b-9 complexes induce proliferative changes of glomerular mesangial cells in rat Thy-1 nephritis through TRAF6-mediated PI3K-dependent Akt1 activation.AMD3100 inhibits brain-specific metastasis in lung cancer via suppressing the SDF-1/CXCR4 axis and protecting blood-brain barrier.CXCL12 and CXCR7 are relevant targets to reverse cell adhesion-mediated drug resistance in multiple myeloma.CXCL12/CXCR4/CXCR7 Chemokine Axis in the Central Nervous System: Therapeutic Targets for Remyelination in Demyelinating Diseases.Hypoxia and hyperoxia differentially control proliferation of rat neural crest stem cells via distinct regulatory pathways of the HIF1α-CXCR4 and TP53-TPM1 proteins.The CXCR4 antagonist plerixafor (AMD3100) promotes proliferation of Ewing sarcoma cell lines in vitro and activates receptor tyrosine kinase signaling.
P2860
Q35078496-FF40412E-1F9D-4AA7-BD2B-DD492AF1050FQ35200250-6C80DA1C-52C1-4FC6-92E6-CD6EAB41014BQ35676034-2005A510-DC9B-4CFD-80A5-60B50B56F2CCQ35794312-66476E8E-68F1-4B8E-9F36-44FB4465743DQ36327374-2480F28C-0E34-4ED7-909F-E4C4AB838A0DQ36796828-F7DB0CB7-42F1-40AC-8B0F-5DB0761AD27EQ38929285-F41CB023-AD1C-4C8E-B088-6068F2EA4171Q42006192-BC8746F8-D1C1-474C-B82E-2606C9F522E0Q42146660-A8756929-82E6-4D04-921E-8C304419DB41Q46762138-4793210F-7163-4D9F-AAA7-38D031612E53Q47220856-8397D975-C947-4A4E-869C-76936B493E57Q48188365-E30AE36A-96B5-429B-97B5-3D90E17D16F5Q49541054-2C2EB502-CD7E-46FB-9446-64B03DB85891Q50467900-FD169EAA-9BE6-4A0F-842E-DF00AA3B0C2BQ54108821-3A95FFD3-9EE9-4C9C-84C5-71AE80C59F7B
P2860
The CXCR4 Antagonist AMD3100 Has Dual Effects on Survival and Proliferation of Myeloma Cells In Vitro.
description
2010 nî lūn-bûn
@nan
2010 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
The CXCR4 Antagonist AMD3100 H ...... ion of Myeloma Cells In Vitro.
@ast
The CXCR4 Antagonist AMD3100 H ...... ion of Myeloma Cells In Vitro.
@en
The CXCR4 Antagonist AMD3100 H ...... ion of Myeloma Cells In Vitro.
@nl
type
label
The CXCR4 Antagonist AMD3100 H ...... ion of Myeloma Cells In Vitro.
@ast
The CXCR4 Antagonist AMD3100 H ...... ion of Myeloma Cells In Vitro.
@en
The CXCR4 Antagonist AMD3100 H ...... ion of Myeloma Cells In Vitro.
@nl
prefLabel
The CXCR4 Antagonist AMD3100 H ...... ion of Myeloma Cells In Vitro.
@ast
The CXCR4 Antagonist AMD3100 H ...... ion of Myeloma Cells In Vitro.
@en
The CXCR4 Antagonist AMD3100 H ...... ion of Myeloma Cells In Vitro.
@nl
P2093
P2860
P1476
The CXCR4 Antagonist AMD3100 H ...... ion of Myeloma Cells In Vitro.
@en
P2093
Deog-Yeon Jo
Ha-Yon Kim
Hwan-Jung Yun
Hyo-Jin Lee
Ji-Young Hwang
Samyong Kim
Seong-Woo Kim
P2860
P304
P356
10.4143/CRT.2010.42.4.225
P577
2010-12-31T00:00:00Z